Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) have received a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $22.75.

Several analysts recently commented on DCPH shares. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Deciphera Pharmaceuticals in a report on Thursday, August 10th. Stifel Nicolaus raised shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price objective for the company from $14.00 to $20.00 in a research report on Wednesday, August 9th. Finally, Piper Sandler raised shares of Deciphera Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $18.00 to $23.00 in a research report on Monday.

Insider Transactions at Deciphera Pharmaceuticals

In other news, EVP Matthew L. Sherman sold 2,942 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $12.68, for a total value of $37,304.56. Following the sale, the executive vice president now owns 84,744 shares in the company, valued at $1,074,553.92. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 4.43% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Deciphera Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Inspire Investing LLC boosted its stake in Deciphera Pharmaceuticals by 10.4% during the third quarter. Inspire Investing LLC now owns 27,532 shares of the company’s stock worth $350,000 after buying an additional 2,583 shares in the last quarter. Sunesis Advisors LLC acquired a new stake in Deciphera Pharmaceuticals during the third quarter worth $1,225,000. SG Americas Securities LLC boosted its stake in Deciphera Pharmaceuticals by 7.9% during the third quarter. SG Americas Securities LLC now owns 165,016 shares of the company’s stock worth $2,099,000 after buying an additional 12,042 shares in the last quarter. Virginia Retirement Systems ET AL acquired a new stake in Deciphera Pharmaceuticals during the second quarter worth $1,056,000. Finally, Nuveen Asset Management LLC boosted its stake in Deciphera Pharmaceuticals by 2.5% during the second quarter. Nuveen Asset Management LLC now owns 1,354,565 shares of the company’s stock worth $19,072,000 after buying an additional 33,549 shares in the last quarter. Institutional investors and hedge funds own 70.96% of the company’s stock.

Deciphera Pharmaceuticals Trading Up 17.5 %

Deciphera Pharmaceuticals stock opened at $11.93 on Tuesday. The stock has a market cap of $940.32 million, a price-to-earnings ratio of -5.14 and a beta of 0.71. The company’s 50-day moving average price is $12.66 and its two-hundred day moving average price is $13.57. Deciphera Pharmaceuticals has a 52 week low of $9.90 and a 52 week high of $22.76.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.05. Deciphera Pharmaceuticals had a negative net margin of 129.90% and a negative return on equity of 47.99%. The company had revenue of $38.30 million during the quarter, compared to analyst estimates of $36.09 million. During the same quarter last year, the firm posted ($0.60) EPS. The business’s revenue for the quarter was up 17.9% on a year-over-year basis. Research analysts expect that Deciphera Pharmaceuticals will post -2.36 earnings per share for the current fiscal year.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.